BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choubey D, Panchanathan R. Interferon (IFN)-inducible Absent in Melanoma 2 proteins in the negative regulation of the type I IFN response: Implications for lupus nephritis. Cytokine 2020;132:154682. [PMID: 30904426 DOI: 10.1016/j.cyto.2019.03.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Niewold TB. Type I interferon. Cytokine 2020;132:155109. [PMID: 32336557 DOI: 10.1016/j.cyto.2020.155109] [Reference Citation Analysis]
2 Fu Q, He Q, Dong Q, Xie J, Geng Y, Han H, Huang Y, Lu J, Zeng Z, Wang W, Chen K, Zhan X. The role of cyclic GMP-AMP synthase and Interferon-I-inducible protein 16 as candidatebiomarkers of systemic lupus erythematosus. Clin Chim Acta 2022;524:69-77. [PMID: 34742679 DOI: 10.1016/j.cca.2021.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Liu Y, Tao X, Tao J. Strategies of Targeting Inflammasome in the Treatment of Systemic Lupus Erythematosus. Front Immunol 2022;13:894847. [PMID: 35664004 DOI: 10.3389/fimmu.2022.894847] [Reference Citation Analysis]
4 Choubey D. Type I interferon (IFN)-inducible Absent in Melanoma 2 proteins in neuroinflammation: implications for Alzheimer's disease. J Neuroinflammation 2019;16:236. [PMID: 31771614 DOI: 10.1186/s12974-019-1639-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
5 Tang L, Zhou F. Inflammasomes in Common Immune-Related Skin Diseases. Front Immunol 2020;11:882. [PMID: 32528469 DOI: 10.3389/fimmu.2020.00882] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]